Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen (INGN) is positioned for growth due to its strong portable oxygen concentrator (POC) market prospects, expanding product portfolio, and international market momentum, despite U.S. revenue pressures. The company is increasing R&D investment and expects continued business improvements, with an attractive valuation based on its P/S ratio. Key risks include macroeconomic factors, supply chain exposure, and reliance on reimbursement for rental economics.
Inogen stock (US45780L1044): respiratory player in focus after Q1 2026 update and restructuring plan
Inogen has reported its Q1 2026 financial results, revealing shrinking revenues but also progress in cost-cutting and cash preservation. The company, which specializes in portable oxygen concentrators, is undergoing restructuring efforts to align its cost base with current revenue levels in a competitive US respiratory care market. Investors are now evaluating the impact of these changes on the company's future profitability and ability to innovate.
Inogen Q1 2026 slides: revenue beats amid profitability pressure
Inogen Inc. (NASDAQ:INGN) reported mixed Q1 2026 results, with revenue of $85.1 million exceeding expectations but GAAP diluted EPS of $(0.30) missing forecasts due to worsening profitability. International sales surged 17.8%, compensating for a 4.8% decline in U.S. sales, while the company's net loss widened and adjusted EBITDA turned negative. Despite strategic investments in R&D and new product launches like the Aurora CPAP mask, profitability challenges persist, as reflected by the stock's 6.2% decline.
Inogen (INGN) TTM Loss Narrows To US$22.7 Million Testing Bearish Profitability Narratives
Inogen (INGN) reported a trailing twelve-month (TTM) net income loss of US$22.7 million for FY 2025, an improvement from a US$35.9 million loss in FY 2024. Despite this narrower loss, the company remains unprofitable and is forecast to continue so for the next three years, with revenue growth projected at 6.4% annually, slower than the broader US market. The stock trades at a low P/S multiple of 0.6x, significantly below peers and its DCF fair value, reflecting investor concerns about its profitability and growth prospects.
Inogen, Inc. (NASDAQ:INGN) Q1 2026 Earnings Call Transcript
Inogen, Inc. reported Q1 2026 revenue of $85.1 million, a 3.4% year-over-year increase, driven by strong international sales, though U.S. sales and rentals saw declines due to shifting market dynamics. The company reaffirmed its 2026 revenue guidance and anticipates adjusted EBITDA growth for the full year, despite increased R&D and marketing investments for new products like the Aurora CPAP mask and Simeox. Inogen aims to expand its addressable market beyond portable oxygen concentrators by annually launching new products in adjacencies like sleep therapy and airway clearance.
Inogen Inc 1Q 2026: Revenue $85.1M, EPS $(0.30) — 10-Q Summary
Inogen Inc (INGN) reported its first-quarter 2026 financial results, with revenue increasing to $85.1M from $82.3M year-over-year. Despite the revenue growth, the company's net loss widened to $8.3M and diluted loss per share increased to $(0.30) from $(0.25) in the prior year. The report also detailed shifts in geographic sales, product expansion, stable gross margins, and operational actions including a share repurchase program.
Inogen Inc stock (US45780L1044): Q1 revenue growth and valuation debate
Inogen Inc reported strong Q1 revenue growth driven by demand for its portable oxygen concentrators, despite the stock trading below analyst price targets. The company's business model focuses on homecare respiratory products, aligning with long-term healthcare trends. However, profitability concerns, cash flow, and sector-specific risks like reimbursement pressures and regulatory changes temper investor enthusiasm.
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen, Inc. (INGN) reported a wider-than-expected adjusted loss per share of 30 cents for Q1 2026, despite revenues increasing 3.4% year over year to $85.1 million, surpassing analyst estimates. The revenue growth was primarily driven by strong international sales, which offset declines in U.S. sales and rentals, and the company also saw an improvement in its adjusted gross margin. Inogen provided Q2 2026 revenue guidance of $94-$97 million and maintained its full-year 2026 revenue outlook of $366-$373 million.
Inogen: Q1 Earnings Snapshot
Inogen Inc. (INGN) reported a first-quarter loss of $8.3 million, translating to 30 cents per share. The Beverly, Massachusetts-based company, which produces oxygen concentrators, announced revenues of $85.1 million for the period. This financial summary was generated by Automated Insights using data from Zacks Investment Research.
Inogen Q1 2026 presentation shows revenue beat, widening losses
Inogen Inc. reported mixed results for Q1 2026, with revenue exceeding expectations at $85.1 million, driven by strong international sales growth of 17.8%. However, the company experienced widening losses, with a diluted EPS of $(0.30) and increased operating expenses due to investments in R&D and strategic initiatives like the Aurora CPAP mask. Despite profitability challenges and a decline in U.S. sales, aftermarket trading saw a slight increase in shares as investors reacted to international expansion and new product launches.
Earnings call transcript: Inogen Q1 2026 shows revenue beat, EPS miss
Inogen Inc. (INGN) reported mixed Q1 2026 results, with revenue of $85.1 million ahead of forecasts by 3.34% due to strong international sales growth, while EPS missed predictions at -$0.30 against -$0.29. Despite the EPS miss, the stock saw a modest 0.7% increase in aftermarket trading, reflecting cautious optimism driven by the revenue beat and strategic product launches like the Aurora CPAP mask. The company reaffirms its 2026 revenue guidance, expecting stronger profitability in Q2 and Q3 due to seasonal trends and continued investment in new markets and product innovation.
Inogen (Nasdaq: INGN) Q1 2026 revenue up 3.4% as losses widen
Inogen reported a 3.4% increase in Q1 2026 revenue to $85.1 million, exceeding its outlook, driven by strong international portable oxygen concentrator demand and favorable foreign exchange rates, despite lower U.S. sales. However, GAAP net loss widened to $8.3 million and adjusted EBITDA became a loss of $1.4 million due to increased R&D investments. The company maintained its full-year 2026 revenue guidance of $366-$373 million and holds a strong cash position of $111.5 million with no debt.
Inogen: Q1 Earnings Snapshot
Inogen Inc. (INGN) reported a loss of $8.3 million in its first quarter, amounting to 30 cents per share. The company, which produces oxygen concentrators, generated $85.1 million in revenue during the period. This financial summary was generated using data from Zacks Investment Research.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
The article "Here's Why You Should Add Inogen Stock to Your Portfolio Now" suggests that Inogen (INGN) is a strong investment choice. It likely details reasons such as the company's market position, financial performance, or future growth prospects that make its stock an attractive addition to an investment portfolio.
Inogen Inc expected to post a loss of 28 cents a share - Earnings Preview
Inogen Inc (INGN) is projected to report a loss of 28 cents per share, according to a Refinitiv earnings preview. This brief article from Reuters highlights the anticipated financial performance for the company.
[ARS] Inogen Inc SEC Filing
This article announces an ARS SEC filing by Inogen Inc. (INGN) on April 28, 2026. The filing has a low impact and neutral sentiment, and the article provides quick links to view the full PDF document and other stock-related data for INGN. It also lists recent news and other SEC filings for the company.
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
Inogen, Inc. (Nasdaq: INGN) announced it will report its first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. The company will also host a conference call on the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Interested individuals can access the call via phone or a live and archived audio webcast on Inogen's Investor Relations website.
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
Inogen, Inc. announced its plan to report first-quarter 2026 financial results after the market closes on Thursday, May 7, 2026. The company will host a conference call on the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Interested individuals can access the call via phone or live audio webcast through Inogen's Investor Relations website.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen (INGN) is positioned for growth in the portable oxygen concentrator (POC) market due to its diversified product portfolio, international expansion, and increasing demand for POCs. While the company faces risks from U.S. revenue pressure and macroeconomic conditions, its attractive valuation and anticipated business improvements suggest it's a stock to retain.
Inogen Inc stock (US45780L1044): Is its portable oxygen model strong enough for long-term investor returns?
Inogen Inc. specializes in portable oxygen concentrators (POCs), targeting the growing home healthcare market with its lightweight devices. The company's business model, which includes direct-to-consumer sales and insurance reimbursements, leverages high barriers to entry and focuses on portability for chronic respiratory patients. While it faces competition and execution risks, Inogen's market position, supported by regulatory tailwinds and an aging population, suggests potential for long-term investor returns, particularly in the United States and other English-speaking markets.
Inogen Inc stock (US45780L1044): Is its portable oxygen model strong enough for long-term investor r
Inogen Inc specializes in portable oxygen concentrators, targeting the growing home healthcare market, particularly for aging populations. The company's model focuses on lightweight, portable devices for chronic respiratory conditions, leveraging direct-to-consumer sales and insurance reimbursements. While positioned for growth due to demographic shifts and regulatory tailwinds, the article highlights challenges such as reimbursement cuts and competitive pressures that could impact long-term investor returns.
Inogen Inc stock (US45780L1044): Why does its portable oxygen model matter more for U.S. investors n
Inogen Inc. specializes in portable oxygen concentrators, targeting the growing home-based respiratory care market driven by aging demographics and Medicare coverage. The company's direct-to-consumer sales and insurance reimbursement pathways, especially in English-speaking regions, underpin its business model. Despite competitive pressures and reimbursement policy risks, Inogen's market leadership and focus on patient independence position it for long-term growth.
Inogen Inc stock (US45780L1044): Is portable oxygen tech strong enough to unlock new upside?
Inogen Inc specializes in portable oxygen concentrators, serving patients with chronic respiratory conditions and capitalizing on the growing demand for home-based healthcare and an aging global population. The company maintains a strong competitive position with its portable, battery-powered devices and direct sales model, differentiating itself from competitors. While facing risks like reimbursement cuts and competition, Inogen's focus on innovation and its presence in key English-speaking markets position it for potential sustained growth.
Inogen Inc (INGN) EVP & CFO Jason Richardson listed in new Form 3 filing
Inogen Inc.'s EVP, CFO & Treasurer, Jason Andrew Richardson, has been listed in a new Form 3 insider report, which is an initial statement of beneficial ownership. The filing indicates no reported buy or sell transactions, derivativepositions, or other related activities, reflecting a neutral impact and sentiment. This Form 3 establishes his initial ownership status as an insider at Inogen Inc., with no current beneficial ownership of securities listed.
Inogen (INGN) grants CFO 100,000 RSUs with multi-year vesting
Inogen Inc. granted its EVP, CFO, and Treasurer, Jason Andrew Richardson, 100,000 restricted stock units (RSUs) on April 6, 2026. These RSUs, each representing a contingent right to one share of Inogen common stock, will vest over three years. One-third of the units vest one year from June 1, 2026, with the remaining portions vesting in equal annual installments, contingent on continued service.
Inogen Inc stock: Fresh Buy rating sparks interest amid recovery potential
Freedom Broker has initiated coverage on Inogen Inc (NASDAQ: INGN) with a "Buy" rating and a $12 price target, indicating a nearly 100% upside from its current trading price of $6.36. Inogen specializes in portable oxygen concentrators for chronic respiratory conditions, a market driven by an aging population and increasing demand for home-based care. The company's expansion into CPAP and stationary units, along with analysts' consensus for significant upside potential, suggests a promising outlook despite competitive risks and potential reimbursement changes.
Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?
Inogen (INGN) shares surged 6.9% on higher-than-average volume, driven by a "Buy" rating and optimistic price target from Freedom Broker, as well as recent governance improvements. While the company anticipates a 4% year-over-year increase in quarterly earnings and a 0.2% rise in revenue, the consensus EPS estimate for the quarter has remained unchanged. Investors are advised to monitor INGN closely for sustained strength, as the stock currently holds a Zacks Rank #3 (Hold).
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen, Inc., a medical technology company, announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective on the date of the Company’s 2026 Annual Meeting. Jamali, a seasoned medical device executive with experience at ZimVie, Covidien, and Medtronic, is expected to bring valuable expertise to help Inogen transition into a diversified respiratory care platform. The appointment is part of a cooperation agreement with Kent Lake Partners LP, which has expressed confidence in Inogen's strategic direction emphasizing organic growth, profitability, innovation, and capital allocation.
Inogen appoints Vafa Jamali to board
Inogen, Inc. has announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective either on June 15th or the date of the Company’s 2026 Annual Meeting. Jamali brings extensive experience as a medical device executive, having previously served as CEO of ZimVie and held senior roles at Covidien and Medtronic. This appointment is expected to support Inogen's strategic transformation from a single-product oxygen company into a diversified respiratory care platform, focusing on growth, profitability, and product innovation.
Inogen Appoints Vafa Jamali to Board
Inogen, Inc. (Nasdaq: INGN) has announced the appointment of Vafa Jamali, a seasoned medical device executive, to its Board of Directors, effective on the date of the Company’s 2026 Annual Meeting or June 15th if earlier. Jamali's extensive experience, including his tenure as CEO of ZimVie and a senior role at Medtronic, is expected to support Inogen's strategic transformation into a diversified respiratory care platform. This appointment is part of a cooperation agreement with Kent Lake Partners LP, which invested in Inogen to support its path of profitable growth and innovation.
Freedom Broker initiates Inogen stock coverage with buy rating on respiratory platform growth
Freedom Broker has initiated coverage on Inogen, Inc. (NASDAQ:INGN) with a buy rating and a price target of $12.00, suggesting an 89% upside from its current trading price of $6.36. The company, a respiratory-focused medtech provider, is transitioning to a broader respiratory care platform, with growth driven by international expansion, B2B channels, and portfolio diversification. Recent developments include an estimated Q4 2025 revenue increase, a $30 million stock buyback program, the launch of Aurora CPAP masks, and significant leadership changes.
Inogen Adds Director Amid Cooperation Agreement With Shareholder
Inogen (INGN) announced the appointment of Vafa Jamali, a seasoned medical device executive, to its board of directors, effective mid-2026. This appointment coincides with a cooperation agreement between Inogen and shareholder Kent Lake Partners, which includes customary standstill and voting commitments, indicating a strategic alignment as Inogen diversifies its respiratory care platform. Spark, TipRanks' AI Analyst, views INGN as "Neutral" due to its transitional phase, citing strategic positives like improved EBITDA guidance against financial performance challenges.
Inogen (Nasdaq: INGN) names Vafa Jamali director and signs cooperation agreement
Inogen Inc. (Nasdaq: INGN) announced the appointment of Vafa Jamali, a veteran medical device executive, as an independent Class I director to its Board. Concurrently, Inogen entered into a cooperation agreement with Kent Lake entities and Benjamin Natter, which includes provisions for voting alignment and standstill restrictions. Jamali will serve on the Audit and Compliance Committees, bringing his extensive experience to guide Inogen's strategic transformation into a diversified respiratory care platform.
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen, Inc. (Nasdaq: INGN) has announced the appointment of Vafa Jamali as an independent director to its Board of Directors, effective on the date of the company's 2026 Annual Meeting or June 15th if earlier. Jamali, a seasoned medical device executive, is expected to bring significant expertise to Inogen as it transforms into a diversified respiratory care platform. The appointment is part of a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter, who expressed confidence in Inogen's strategic direction.
Inogen appoints Jason Richardson as CFO to support growth
Inogen, Inc. has announced several leadership appointments, including Jason Richardson as the new Chief Financial Officer, effective April 6, 2026. Richardson, who previously held senior finance roles at Baxter International Inc., succeeds Michael Bourque. The company also appointed Dominic Hulton as Chief Marketing Officer and Corey Moritz as Vice President, U.S. Business to Business Sales, with these changes aimed at accelerating Inogen's growth and strengthening its market presence.
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN) announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 10:15 a.m. Eastern Time. A live audio webcast will be available on Inogen's Investor Relations website. Inogen is a medical technology company focusing on innovative respiratory products for homecare settings.
Inogen CEO to speak April 14 at Needham healthcare event
Inogen, Inc. announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The company, which is a medical technology firm specializing in respiratory products, will make a live audio webcast and archived recording of the presentation available on its investor relations website. This announcement also highlights Inogen's commitment to Regulation FD by using its Investor Relations website for disclosing material non-public information.
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN) announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The medical technology company, which specializes in innovative respiratory products for homecare, will make a live audio webcast and archived recording of the presentation available on its investor relations website. The press release also includes forward-looking statements regarding Inogen's future business plans, market opportunities, and financial outlook.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced the approval of inducement grants of restricted stock units (RSUs) to its new Chief Financial Officer, Jason Richardson, and Chief Marketing Officer, Dominic Hulton. These equity awards, made under Nasdaq Listing Rule 5635(c)(4), are a material inducement for their employment with the company. The grants include time-based and performance-based RSUs for Mr. Richardson and time-based RSUs for Mr. Hulton, vesting over three years subject to continued service.
Inogen appoints Jason Richardson as CFO; Michael Bourque to step down, remain as Senior Advisor
Inogen has appointed Jason Richardson as its new Executive Vice President, Chief Financial Officer, and Treasurer, effective April 6, 2026. Current CFO Michael Bourque will step down but remain as a Senior Advisor until June 30, 2026. Richardson previously served as CFO and VP of Health System and Technologies Segment at Baxter.
Inogen makes three appointments to exec team
Inogen has appointed three new members to its executive team to accelerate its next phase of growth. Jason Richardson will serve as CFO, Dominic Hulton as chief marketing officer, and Corey Moritz as vice president, U.S. business-to-business sales. These strategic hires bring extensive experience in finance, marketing, and commercial transformation from the medical device and healthcare industries.
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN) announced that its President and CEO, Kevin Smith, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. A live audio webcast and archived recording of the presentation will be available on the company's Investor Relations website. Inogen is a medical technology company specializing in innovative respiratory products for homecare settings.
Inogen appoints new CFO
This article announces that Inogen has appointed a new Chief Financial Officer.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced inducement grants of restricted stock units to Jason Richardson, the new Chief Financial Officer, and Dominic Hulton, the new Chief Marketing Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Richardson received 200,000 RSUs (half time-based, half performance-based), while Mr. Hulton received $200,000 in time-based RSUs. These awards are intended to attract and retain key talent and will vest over three years, subject to continued employment and performance goals for Mr. Richardson.
Inogen (INGN) Reaffirms FY26 Revenue Outlook Amid Market Adjustm
Inogen (INGN) has reaffirmed its fiscal year 2026 revenue forecast, projecting between $366 million and $373 million, aligning with analyst expectations. The company, which specializes in respiratory health products, exhibits mixed financial health with strong gross margins but negative profitability metrics and an Altman Z-Score indicating potential distress. Despite the financial challenges, valuation metrics suggest the stock may be undervalued, and institutional ownership remains high.
Inogen (NASDAQ: INGN) appoints new CFO and growth-focused commercial leaders
Inogen, Inc. (NASDAQ: INGN) announced key leadership changes, including the appointment of Jason Richardson as the new CFO, effective April 6, 2026, succeeding Michael Bourque. The company also appointed Dominic Hulton as Chief Marketing Officer and Corey Moritz as Vice President, U.S. Business to Business Sales, to accelerate its growth strategy. Inogen reaffirmed its first-quarter and full-year 2026 financial outlook, indicating that these executive appointments do not alter its near-term financial expectations.
New Inogen finance and marketing chiefs get stock awards to join
Inogen, Inc. announced inducement stock awards for its new Chief Financial Officer, Jason Richardson, and Chief Marketing Officer, Dominic Hulton. These awards, consisting of restricted stock units (RSUs) and performance-based restricted stock units (PSUs), were granted under Nasdaq Listing Rule 5635(c)(4) to attract the new executives. The grants aim to align the executives' compensation with the company's performance and their continued service.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced inducement grants of restricted stock units to its new Chief Financial Officer, Jason Richardson, and Chief Marketing Officer, Dominic Hulton. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize their employment with the company. Richardson will receive equity awards covering 200,000 shares, comprising both time-based and performance-based restricted stock units, while Hulton will receive $300,000 in time-based restricted stock units.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. announced the granting of restricted stock units to new hires Jason Richardson, Chief Financial Officer, and Dominic Hulton, Chief Marketing Officer, as an inducement for their employment. These equity awards, approved by the Compensation Committee, are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to attract top talent to the medical technology company. The grants consist of both time-based and performance-based restricted stock units, vesting over three years, and were issued outside of the company's stockholder-approved equity plan.
Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth
Inogen, Inc. has announced several key leadership appointments to accelerate its next phase of growth. Jason Richardson has been named Chief Financial Officer, succeeding Michael Bourque. Dominic Hulton has been appointed Chief Marketing Officer, and Corey Moritz has joined as Vice President, U.S. Business to Business Sales. The company also reaffirmed its financial outlook for the first quarter and full year 2026.
